IGF signaling pathway as a selective target of familial breast cancer therapy

Vivek Shukla, Xavier Coumoul, Athanassios Vassilopoulos, Chu Xia Deng*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Hereditary breast cancers affect women who have an increased risk of developing tumors because of a familial history. In most cases, they can be attributed to mutations in the breast cancer associated gene 1 and 2 (BRCA1 and BRCA2). Recent studies have demonstrated a link between the insulin-like growth factor (IGF) signaling pathway and familial breast cancer incidence. IGF and IGF receptors represent a family of biological growth factors and transducers, which have been involved in both physiological and pathological processes. It has been shown that BRCA1 regulates expression of several members of the IGF family. Here, we will examine our understanding of the functions of IGF/IGF-receptor signaling, the development of new inhibitors of this pathway and the related mechanisms of familial breast cancer formation.

Original languageEnglish (US)
Pages (from-to)727-740
Number of pages14
JournalCurrent Molecular Medicine
Volume8
Issue number8
DOIs
StatePublished - 2008

Keywords

  • BRCA1
  • IGF/IGF-receptor
  • Inhibitor
  • Mouse model
  • SiRNA

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Fingerprint

Dive into the research topics of 'IGF signaling pathway as a selective target of familial breast cancer therapy'. Together they form a unique fingerprint.

Cite this